Top Markets
#1 Akedo Akedo +71.59%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.61%
#4 Cross Cross +34.10%
#5 Black Phoenix Black Phoenix +33.95%
#6 Cap Cap +29.61%
#7 Velvet Velvet +26.32%
#8 Ravencoin Ravencoin +17.91%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.35%
#10 DoubleZero DoubleZero +12.07%
Coin of the day
Akedo Akedo
설정
언어
한국어
통화
USD
테마
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
주식 순위 #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
주가
$0.073
시가총액
$849.99K
변동 (1일)
4.29%
변동 (1년)
21.67%
국가
US
거래 Hepion Pharmaceuticals, Inc. (HEPA)

카테고리

Healthcare
Hepion Pharmaceuticals, Inc. (HEPA)의 매출
Aug 2026 기준 매출 TTM: 0
Hepion Pharmaceuticals, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Hepion Pharmaceuticals, Inc.의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE